StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.52+0.18 (+4.15%)

Close on Nov 19, 2026Market cap $504.03MP/E –Yield –

Gyre Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Gyre Therapeutics's pe ratio was 384.0× on Apr 30, 2026, against 195.2× a year earlier. Over the last 3 years it ranged from 5.4× to 453.5×, with a median of 84.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 2026384.0×+261.2
2025Dec 31, 2025122.8×+113.4
2023Jul 31, 20239.3×−12.2
2022Dec 30, 202221.5×−36.1
2011Oct 31, 201157.6×–

More Gyre Therapeutics figures

See a number that looks wrong?